Sotatercept significantly increased the distance that cardiovascular patients could walk over a 24-week period. Patients in the trial also saw improvements in eight of the nine outcome measures for cardiovascular patients set by the World Health Organization.
The trial also found sotatercept reduced the risk of clinical worsening or death by 84 percent compared to a placebo, according to a March 6 press release.
